Morepen Laboratories has informed that the Board of Directors of the company, in their meeting held on Wednesday, 31st January 2024 (commenced at 11:30 am and concluded at 2:05 pm), have considered and approved the followings: Unaudited standalone and consolidated financial results of the company for the quarter and nine months ended 31st December 2023, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The ‘Results’ along-with the ‘Limited Review Report’ of the Auditors of the company for the quarter and nine months ended 31st December 2023, are enclosed and Appointment of Vikas Sharma, Talent Acquisition & HRBP, Functional Head, a Senior Management Personnel. The necessary details as per sub-para 7 (C) of Para A Part A of Schedule III SEBI (LODR) Regulations read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, is enclosed.
The above information is a part of company’s filings submitted to BSE.